about
sameAs
Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skinComparative Analysis of Two Gene-Targeting Approaches Challenges the Tumor-Suppressive Role of the Protein Kinase MK5/PRAKThe p38 MAPK regulates IL-24 expression by stabilization of the 3' UTR of IL-24 mRNA.Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect.Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models.Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-αIκBζ is a key driver in the development of psoriasis.STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes.The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice.Leptin deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes.Tumor necrosis factor-alpha-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappaB.Tumor necrosis factor α-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor κB.1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression.IκBζ: A key protein in the pathogenesis of psoriasis.Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice.MicroRNA normalization candidates for quantitative reverse-transcriptase polymerase chain reaction in real time in lesional and nonlesional psoriatic skin.MK2 regulates the early stages of skin tumor promotion.IL-8 and p53 are inversely regulated through JNK, p38 and NF-kappaB p65 in HepG2 cells during an inflammatory response.Interleukin-23 in early disease development in rheumatoid arthritis.Interleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules.Measuring serum concentrations of interleukin-33 in atopic dermatitis is associated with potential false positive results.A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis.Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2.The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin.IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab.Role of p38 mitogen-activated protein kinase isoforms in murine skin inflammation induced by 12-O-tetradecanoylphorbol 13-acetate.TNFα- and IL-17A-mediated S100A8 expression is regulated by p38 MAPK.1alpha,25-dihydroxyvitamin D3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinase/Ras/MEK/extracellular signal regulated kinase 1/2 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fra1, and c-Jun expressMice lacking MSK1 and MSK2 show reduced skin tumor development in a two-stage chemical carcinogenesis model.Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin.CCL27 expression is regulated by both p38 MAPK and IKKβ signalling pathways.Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice.The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling.Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin.Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases.Protein phosphatase 2Cδ/Wip1 regulates phospho-p90RSK2 activity in lesional psoriatic skin.The role of leptin in psoriasis comprises a proinflammatory response by the dermal fibroblast.Langerhans cell markers CD1a and CD207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment.Generation and Culturing of Primary Human Keratinocytes from Adult Skin.Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study.
P50
Q28301222-0BD5E885-188B-4663-A9FB-6C32FDE7CCEAQ28301222-CD27DA46-8499-4673-8FF5-78040B0395FAQ28547394-EE97675F-EF35-44C9-999A-AF8EC1CAA7C8Q33523814-9ECD44D7-F980-4CDC-A165-F7842B6C2CECQ34627517-226C42D0-AFC9-4E9F-B737-FB90432CF9D3Q34627517-DCDBD209-309F-4A70-931A-C830CE5E9C51Q35045606-A385860F-3839-47CB-BF01-1EACF5478AB8Q35045606-B2B45409-BE01-4D92-9CEA-873088D051ABQ36231590-A5923363-AB53-439D-9510-A45466ED0479Q36231590-BF5CFA13-1FDC-4E77-9668-6BF9563E4BD5Q36238508-044F0B8D-4EBC-457D-B73A-380E09AA6AF7Q36238508-19DA7FA4-DCE0-43EF-8C17-5DE005D72785Q36363330-315BB3F3-49E0-4B0E-BE90-2D3E538146DBQ36363330-ED0DED65-63BF-4FD3-B6FC-E2C595643F04Q37326495-09EE2A55-A4BF-4C84-88A8-6E03ED1EF42EQ37326495-503B4019-0CD9-41FB-9BB9-DFE725297006Q38291462-5829ED6C-2338-4EF7-A259-F40BEA64C56CQ38291462-E2935C92-EC59-44A5-BF92-CA83237FDFB8Q38333148-09A943CE-CF95-42F2-A06A-25CA6A5491B4Q38333148-C3A2DF79-70FA-44B7-A977-521636EB07E9Q38334718-3E38E615-D4F1-4559-9013-052FA99A3A99Q38334718-A8766C66-6276-4D07-8B69-751D97C1755DQ38336576-0123022F-0DD5-4E6E-84A3-49F41218F1A5Q38336576-727D3F55-C44E-4465-8EF9-A46A04FD8C4AQ38937698-307AE17F-C4B6-4095-B4D8-D4016AC8ECDFQ38937698-E52C007E-8FBB-410A-B908-FAA770D17669Q38937859-9138ECE8-264A-4F7A-9F08-4EEB567FABCEQ38937859-99317C96-99AF-4FD9-AE26-B81C9A3D3105Q39437081-3C6F9B82-69EE-4312-9455-AC8107E7E0E1Q39437081-A1C8978D-6091-4831-BE1D-D602A8E5AB3AQ39941132-B68D3C5B-7B29-4ADC-983F-BD4A6DCF4C00Q39941132-E2B31C57-7512-44AF-9485-8C3DE0DB0EFAQ39964041-A6F00CEC-4CC2-4C7B-8251-1F6AEE970ABAQ39964041-D968D3C2-59CE-4E01-9476-6AC4555853C3Q40823087-C7A9512A-55AD-4310-A549-F44E6BD06C45Q41946482-67844DBA-B3DE-476B-89BA-79AA8D7A0C2EQ42046007-A70A1135-0B1F-41C0-BA6A-95DDBCEEB753Q42046007-AA7DEBAC-4380-4854-A02E-081F84065B05Q42468308-012D319A-69AA-4D81-9D61-5CAE1049735FQ42468308-54CD856C-BFE5-422B-8891-6625315160CD
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Claus Johansen
@ast
Claus Johansen
@en
Claus Johansen
@es
Claus Johansen
@nl
type
label
Claus Johansen
@ast
Claus Johansen
@en
Claus Johansen
@es
Claus Johansen
@nl
prefLabel
Claus Johansen
@ast
Claus Johansen
@en
Claus Johansen
@es
Claus Johansen
@nl
P106
P31
P496
0000-0002-5665-5212
0000-0003-0240-5127